AI Trends

Google-affiliated AI drug discovery company Isomorphic Labs completes $5 billion Series C funding

Sina TechUpdated Nov 18 14:03

AI summary

Isomorphic Labs announced on November 17 that it had completed a $5 billion Series C funding round, co-led by Greenoaks and Sequoia Capital, with new investors including a16z participating, Alphabet continuing to invest on a large scale, and existing investors including Temasek, Thrive Capital, and MGX also taking part. This round sets a new global record for the scale of a single funding round in the AI drug discovery field, coming just half a year after its $2.1 billion Series B round in May this year; the company's cumulative publicly disclosed funding has now reached $7.7 billion. The company's core technology is the drug design engine IsoDDE, which integrates foundational simulation AI models with proprietary Agents, and it has established R&D collaborations with pharmaceutical companies such as Novartis, Eli Lilly, and Johnson & Johnson; Hassabis said in January this year that he expected the first batch of clinical trials to begin before the end of 2026, a delay from the previous target of the end of 2025.

Why read this

AI score 67

The $5 billion Series C round sets a new record for a single funding round in AI drug discovery; the original article also sets out the capability boundaries of the IsoDDE engine and the delay in the clinical trial timetable.

Topics

Tags

Body · AI translation

Add new crowd-testing promotional copy Add new crowd-testing promotional copy end Add App-exclusive traffic diversion

On November 17 local time, Google-affiliated AI drug discovery company Isomorphic Labs announced the completion of a $5 billion (approximately RMB 35.5 billion) Series C funding round, co-led by Greenoaks and Sequoia Capital, with new investors including a16z participating, and Google parent company Alphabet continuing to invest on a large scale. Existing investors such as Temasek, Thrive Capital, and MGX also participated.

This funding round set a new record for the largest single funding round in the global AI drug discovery field, coming only half a year after Isomorphic Labs' previous funding round. In May of this year, the company had just secured $2.1 billion in Series B funding, which also set a record for the largest single funding round in the global AI drug discovery industry at the time. Combined with the $600 million first external funding completed in March 2025, this company, founded only five years ago, has disclosed cumulative funding of $7.7 billion.

Isomorphic Labs was founded in the UK by Nobel Prize in Chemistry laureate and former Google DeepMind co-founder Demis Hassabis. The company was spun off from Google DeepMind in 2021, with Hassabis serving as CEO. In August of this year, after Hassabis stepped down as CEO of Google DeepMind, he focused on long-term AGI strategy, AI's social impact, and this AI drug discovery company Isomorphic Labs.

Why are investors willing to pour huge sums into an AI company that has not yet brought a drug to market? For Hassabis, this is the next major scientific breakthrough he is attempting to achieve with AI, following AlphaFold's success in predicting protein structures.

Traditional new drug development is a long and expensive process. Researchers need to search through massive numbers of compounds for potentially effective candidate molecules, then repeatedly optimize their efficacy, safety, and other characteristics through experiments. Even after entering clinical trials, the risk of ultimate failure remains high.

Isomorphic Labs hopes to greatly improve the efficiency of this process through AI. Its core technology is the proprietary drug design engine IsoDDE, which integrates a series of foundational simulation AI models covering multiple therapeutic areas and different drug types, capable of exploring chemical space and helping R&D teams design, screen, and optimize molecules with desirable drug-like properties.

In addition to simulation models, the company has also developed proprietary Agents for exploring complex biological systems and performing reasoning. Isomorphic Labs says that combining models with Agents has advanced pipelines of multiple types of drug candidates. Currently, the company's internal oncology and immunology projects as well as collaborative projects have achieved preclinical results.

Isomorphic Labs stated that it has established R&D partnerships with large pharmaceutical companies such as Novartis, Eli Lilly, and Johnson & Johnson to explore the application of AI in different drug R&D projects.

In a blog post, Hassabis mentioned that when founding Isomorphic Labs, the team believed that biology could be understood and modeled at the most fundamental molecular level, and that AI could significantly accelerate this process. According to him, this funding round will help the company further develop foundational biology models, increase understanding of disease mechanisms, and advance the first batch of therapeutic programs into clinical trials to provide patients with a new generation of medicines.

However, in contrast to the huge funding, Isomorphic Labs still has a long way to go before launching a drug that can be sold on the market.

In January of this year, Hassabis said at the World Economic Forum in Davos that the company expected to launch its first clinical trials by the end of 2026. This timeline has already been delayed compared with the previously stated target of the end of 2025.

This is also the core problem that the AI drug discovery industry has not yet solved: although AI can accelerate the discovery of drug molecules, whether these molecules can become safe and effective drugs still requires lengthy verification. Drug development must not only prove that it can treat human diseases, but also ensure that it does not produce major side effects.

Some industry practitioners believe that although the AI drug R&D field has huge capital bets, the risk of clinical trial failure remains high, "because huge amounts of money cannot guarantee the launch of market-ready drugs." Improved model predictive capability does not mean that the entire clinical development cycle can be shortened proportionally.

Isomorphic Labs is undergoing another form of commercialization test in the AI industry. In the past few years, the market has been accustomed to evaluating the value of AI companies through model rankings, generation speed, and user scale. But in the pharmaceutical field, model performance is only the starting point; ultimately, clinical trial results are needed to prove the actual value of the technology.

Compared with "half of the timeline being spent on spending billions of dollars to make chatbots more interesting," some netizens believe that $5 billion spent on tackling diseases seems more worthy of attention. If AI's first truly killer app is not an app but a drug, that is the plot twist he is looking forward to.

"Using AI to improve human health is one of the most important challenges facing our generation," said a partner at investor Sequoia Capital, expressing their hope to help drive further scientific discoveries in medicine. Statement: This is an exclusive article from Sina.com. Reproduction without authorization is prohibited. tech_web_article_v2015_block_bottom Non-targeted 300*250 button 17/09 wenjing begin

Non-targeted 300*250 button end

Source

Sina Tech